# Vara

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vara

- Industry: Medical Devices & Equipment
- Headquarters: Berlin, Germany
- Website: www.vara.ai
- Total disclosed funding: $15M
- Latest round: Series A (Jun 22, 2022)
- Investors on record: 8

## About

Vara is a Berlin-based company that enhances breast cancer screening through an AI-powered platform, streamlining the screening process for patients and healthcare providers alike.Founded in 2018 in Berlin, Germany, Vara specializes in breast cancer screening solutions. The company has undergone no significant pivots and operates independently. The founders are Jonas Muff and Stefan Bunk, with Jonas Muff serving as the CEO. In June 2022, Vara raised USD 4.4 million in Series A funding, led by Vi Partners and joined by EQT AB (PUBL), Soleria Capital, and Think.Health Ventures, bringing their total amount raised to USD 4.4 million and a current valuation of USD 26.64 mn.Vara provides comprehensive solutions for breast cancer screening, focusing on enhancing accessibility and effectiveness. Their core product is an AI-powered platform that streamlines the screening pathway, including appointment booking, radiology center management, scan reading, histopathology reporting, and results communication. Their solutions are currently evaluated in various markets, including Germany, emphasizing evidence-based validation.Vara's revenue model is based on partnerships and subscriptions with healthcare institutions and radiology centers using their screening solutions. Clients subscribe to access advanced screening technologies and may engage in performance-based agreements tied to cancer detection effectiveness and operational enhancements. Specific pricing plans are not disclosed, but the model reflects a commitment to delivering value to healthcare providers through improved patient outcomes and efficiencies.Following their recent funding round in June 2022, Vara plans to enhance its breast cancer screening solutions by making them more data-driven. The company aims to expand into new markets and geographic regions, although specific targets have not been disclosed. The funding will support the development of upcoming products and the enhancement of their current offerings, aligning with their strategic goal of improving breast cancer detection.

## Funding rounds

- Series A, Jun 22, 2022, $4.4M — Vi Partners, Think.Health Ventures, Soleria Capital, EQT AB (PUBL)
- Series A, May 20, 2020, $7.1M — OMERS Ventures, Plug and Play, PNP Capital, Think.Health Ventures, Soleria Capital, Merantix Capital
- Seed, Nov 22, 2018, $3.4M — Merantix Capital

## Investors

- Merantix Capital (https://capitalatlas.ai/funds/merantix-capital) — Seed, Series A
- OMERS Ventures (https://capitalatlas.ai/funds/omers-ventures) — Series A
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Series A
- PNP Capital — Series A
- Think.Health Ventures (https://capitalatlas.ai/funds/think-health-ventures) — Series A
- Soleria Capital (https://capitalatlas.ai/funds/soleria-capital) — Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A
- EQT AB (PUBL) — Series A